Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer
- Conditions
- Breast Cancer Recurrent
- Interventions
- Registration Number
- NCT06458413
- Lead Sponsor
- Min Yan, MD
- Brief Summary
This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.
This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.
- Detailed Description
Patients with recurrent or metastatic HER2 negative breast cancer who have previously received chemotherapy containing taxanes and/or anthracyclines will receive combined treatment with utidelone capsule and capecitabine. Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14. Every 21 days is a cycle until disease progression, intolerable adverse events occur, subjects voluntarily withdraw, or the researcher determines that medication must be terminated.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 40
-
Voluntarily participate in this study, sign an informed consent form, have good compliance, and are willing to follow-up.
-
Female, aged ≥ 18 and ≤ 70 years, with an ECOG score of 0-1 and an expected survival time of ≥ 12 weeks.
-
The pathological and/or cytological diagnosis (based on the latest biopsy results) is HER2 negative recurrent or metastatic breast cancer, regardless of hormone receptor status (ER/PR positive or negative, but the hormone receptor status needs to be determined);
-
All patients have received at least paclitaxel and/or anthracycline as a treatment option;
-
All patients with prior treatment ≤ 3 lines (for those who progress during the neoadjuvant/adjuvant period or within 12 months after the end of the last treatment, it is considered as the first line, and no progress is counted as the number of lines); For HR+/HER2- breast cancer patients, they also need to have received the first line systemic CDK4/6 inhibitor+endocrine therapy before the disease progresses.
-
According to RECIST 1.1 standard, there is at least one measurable extracranial lesion present.
-
Within one week before enrollment, the blood routine examination was basically normal (no blood transfusion within two weeks, no use of drugs to increase white blood cells or platelets):
Neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count (PLT) ≥ 90 × 109/L; Hemoglobin ≥ 9.0 g/dL.
-
Within one week before enrollment, the blood biochemistry test was basically normal (based on the normal values of each research center laboratory): Total bilirubin (TBIL) ≤ 1.5 x Upper limit of normal value (ULN) SGPT/ALT ≤ 3 × ULN (liver metastasis patients ≤ 5 × ULN); SGOT/AST ≤ 3 × ULN (liver metastasis patients ≤ 5 × ULN); The creatinine clearance rate (Ccr) is ≥ 50 ml/min (Cockcroft Gault formula).
-
No major organ dysfunction
-
Women with fertility must agree to use effective contraceptive methods during the study period and within 6 months after the last study medication. Women with fertility must have a negative blood or urine pregnancy test before enrollment.
-
Other malignant tumors within the 5 years prior to enrollment, excluding cured cervical carcinoma in situ, basal cell carcinoma of the skin, papillary thyroid carcinoma without lymph node metastasis, or squamous cell carcinoma of the skin.
-
Those who meet the following conditions:
- Received systemic anti-tumor therapy within 2 weeks prior to enrollment, including but not limited to endocrine therapy, small molecule targeted therapy, anti-tumor traditional Chinese medicine, etc;
- Within the 4 weeks prior to enrollment, chemotherapy, targeted biological therapy or immunotherapy, other clinical investigational drugs, radiation therapy, or major organ surgery (excluding biopsy) or significant trauma have been received, or elective surgery is required during the trial period. Those who have undergone major surgeries;
- Received nitroso urea or mitomycin C within 6 weeks prior to enrollment;
-
Individuals who have previously received treatment with Utidelone injection.
-
Peripheral neuropathy CTCAE 5.0 grade evaluation ≥ 2.
-
Those who have received treatment with capecitabine or other drugs with an active ingredient of 5-fluorouracil (excluding those who relapse after more than 12 months of treatment).
-
Pregnant and lactating patients.
-
Adverse reactions from previous anti-tumor treatments have not yet recovered to CTCAE 5.0 grade ≤1 (excluding toxicity judged by researchers to have no safety risk for hair loss).
-
Accompanied by meningeal metastasis; Accompanied by uncontrollable brain metastases (researchers have determined that new asymptomatic brain metastases or those known to have stable brain metastases after treatment can be enrolled); Or uncontrollable bone metastasis, which refers to patients who have or have recently been at risk of fractures or have obvious symptoms or other critical situations.
-
Uncontrollable pleural effusion, pericardial effusion, or abdominal effusion.
-
Individuals with active infections who currently require systematic anti infection treatment.
-
Have a history of immunodeficiency, including HIV antibody testing positive, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation.
-
Individuals with active hepatitis B or hepatitis C; Known active syphilis infection.
-
Have a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:
Serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade II-III atrioventricular block, etc; At rest, the average QTcF obtained from three 12 lead electrocardiogram examinations is>470ms; Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade 3 or higher cardiovascular events occurring within 6 months prior to the first administration; Hypertension that cannot be controlled clinically. Other researchers have identified high-risk heart diseases.
-
Uncontrolled diabetes patients.
-
Patients with active gastrointestinal ulcers.
-
Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia.
-
Participate in another clinical trial or use other investigational treatments simultaneously.
-
Individuals known to be allergic to the investigational drug or any of its excipients.
-
The researchers believe that the subjects have a history of other serious systemic diseases or other reasons that make them unsuitable to participate in this trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single-arm Utidelone Capsule Plus Capecitabine Patients with HER2-negative breast cancer were treated with Utidelone Capsule combined with Capecitabine tablets.
- Primary Outcome Measures
Name Time Method Objective Response Rate （ORR） 18 months ORR is defined as the percentage of participants in the analysis population who have CR or PR per RECIST 1.1.
- Secondary Outcome Measures
Name Time Method Progression-Free Survival（PFS） 18 months time from the first dose to disease progression or any-cause death
Disease Control Rate （DCR） 18 months DCR is defined as the percentage of participants in the analysis population who have CR or PR or SD per RECIST 1.1.
Duration of response (DoR) 18 months DOR is defined as the interval from response initiation (when either CR or PR is first determined) to progression or death, whichever occurs first.
Overall survival (OS) 18 months time from the first dose of study drug to any-cause death
Treatment-related Adverse Event-TRAE Until 28 days after the last dose of treatment Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Trial Locations
- Locations (1)
Henan Cancer hospital
🇨🇳Zhengzhou, Henan, China